Leerink Partnrs Has Positive Forecast for STOK Q3 Earnings

Key Points

• Leerink Partners has revised its Q3 2025 earnings per share (EPS) forecast for Stoke Therapeutics to ($0.64), slightly up from the prior estimate of ($0.65).
• The company reported Q2 earnings of ($0.40) EPS, exceeding analysts' expectations of ($0.57), with revenues of $13.82 million compared to expected $31.51 million.
• Stoke Therapeutics has a consensus rating of "Buy" among analysts, with an average price target of $25.17, reflecting investor confidence in its future performance.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Investment analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for Stoke Therapeutics in a research note issued on Tuesday, August 12th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings per share of ($0.64) for the quarter, up from their prior forecast of ($0.65). The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. Leerink Partnrs also issued estimates for Stoke Therapeutics' Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at $0.20 EPS, FY2026 earnings at ($3.65) EPS, FY2027 earnings at ($3.10) EPS and FY2028 earnings at ($1.40) EPS.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. The firm had revenue of $13.82 million during the quarter, compared to analysts' expectations of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%.

STOK has been the subject of a number of other reports. Chardan Capital reiterated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday. HC Wainwright cut their price target on shares of Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating on the stock in a report on Wednesday, May 14th. Cantor Fitzgerald upgraded shares of Stoke Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Needham & Company LLC restated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, July 1st. Finally, Jefferies Financial Group began coverage on shares of Stoke Therapeutics in a report on Friday, July 18th. They set a "buy" rating and a $30.00 price target on the stock. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Stoke Therapeutics has a consensus rating of "Buy" and an average price target of $25.17.

Stoke Therapeutics Price Performance

Shares of NASDAQ STOK opened at $17.17 on Friday. The stock has a market capitalization of $940.92 million, a P/E ratio of 20.20 and a beta of 1.15. The company has a 50-day moving average price of $12.41 and a 200-day moving average price of $10.11. Stoke Therapeutics has a 1 year low of $5.35 and a 1 year high of $17.61.

Insiders Place Their Bets

In other Stoke Therapeutics news, insider Barry Ticho sold 6,471 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $10.03, for a total value of $64,904.13. Following the transaction, the insider directly owned 25,782 shares in the company, valued at $258,593.46. The trade was a 20.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 12,720 shares of company stock valued at $140,095 in the last 90 days. 9.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its position in shares of Stoke Therapeutics by 2.9% in the second quarter. Bank of America Corp DE now owns 548,090 shares of the company's stock valued at $6,221,000 after purchasing an additional 15,206 shares during the period. MPM Bioimpact LLC raised its position in shares of Stoke Therapeutics by 13.8% in the second quarter. MPM Bioimpact LLC now owns 789,698 shares of the company's stock valued at $8,963,000 after purchasing an additional 95,710 shares during the period. Jane Street Group LLC raised its position in shares of Stoke Therapeutics by 28.8% in the second quarter. Jane Street Group LLC now owns 34,743 shares of the company's stock valued at $394,000 after purchasing an additional 7,765 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Stoke Therapeutics by 121.0% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 53,411 shares of the company's stock valued at $607,000 after purchasing an additional 29,244 shares during the period. Finally, The Manufacturers Life Insurance Company raised its position in shares of Stoke Therapeutics by 14.1% in the second quarter. The Manufacturers Life Insurance Company now owns 15,099 shares of the company's stock valued at $171,000 after purchasing an additional 1,862 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.